Latest Articles
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Published: Aug. 28, 2025, 8:24 a.m.
Sirtuin 6 Mediates the Therapeutic Effect of Endometrial Regenerative Cell-derived Exosomes in Alleviation of Acute Transplant Rejection by Weakening c-Myc-dependent Glutaminolysis - Frontiers
Sirtuin 6 Mediates the Therapeutic Effect of Endometrial Regenerative Cell-derived Exosomes in Alleviation of Acute Transplant Rejection by Weakening c-Myc-dependent Glutaminolysis Frontiers
Published: Aug. 27, 2025, 8:36 a.m.
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 7:31 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News
Published: Aug. 26, 2025, 6:04 p.m.
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 5:39 p.m.
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer - Curetoday
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer Curetoday
Published: Aug. 26, 2025, 4:06 p.m.
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG
Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG
Published: Aug. 26, 2025, 3:07 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Link copied to clipboard!